China Tries Out Patent Auction for Biologics
This article was originally published in PharmAsia News
Executive Summary
At a recent patent transfer auction in Shanghai, eight patents were up for grabs, with three of them biomedical intellectual properties. A drug manufacturer under Guangming Group managed to clinch Shanghai Newsummit Biopharma's patented freeze-dry recombinant human growth factor-2 at RMB 18 million. The patented drug received clinical trial approval in July 2005 and is now undergoing a Phase III trial. The product is expected to get a new drug license soon, paving the way for its marketing. Local pharmaceutical companies prefer to invest in a promising drug as higher risks abound during early R&D stages. Experts point out that auctions represent only a means of technology transfer; more critical are market predictions and risk assessments of a product. (Click here for more - Chinese Language)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.